Beyond PD-L1 expression, a 6-gene interferon gamma (IFNγ)-related signature based on gene expression profiling was tested in a small population of pembrolizumab-treated patients with G/GEJ adenocarcinoma (N = 33) [9]. This evidence concerns the gene IFNG and adenocarcinoma.